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Sir,
We appreciate the data and comments provided by Langma ´r
et al (2011) regarding our recent report ‘HE4 and CA125 as a
diagnostic test in ovarian cancer: prospective validation of the Risk
of Ovarian Malignancy Algorithm’ (Van Gorp et al, 2011).
In their letter Langma ´r et al suggest that we did not start this
prospective study as a generic pelvic mass diagnostic study. They
draw this conclusion by the fact that we started this study in 2005,
and yet the studies from Moore et al were only published in 2008
and 2009 (Moore et al, 2008, 2009). However, we must point out
that several publications on HE4 were already published between
2003 and 2005 (Hellstrom et al, 2003; Lu et al, 2004; Drapkin et al,
2005; Rosen et al, 2005). Between August 2005 and March 2009, 432
consecutive patients with a pelvic mass, who planned to undergo
an operation, were eligible to participate in our study. Five patients
withdrew consent during the study. Seventeen patients did not
have the serum sample taken, or the volume of the retrieved serum
was insufficient to perform the marker assays. Pathology reports
were missing in 21 patients because the patients were eventually
not operated upon due to poor prognosis or patients’ decline, or
because there was no biopsy taken and therefore no proven
histological diagnosis. The remaining 389 patients participated in
this study. In 2008 we were confronted with the results from Moore
and colleagues. Since they published a significant difference
between the performance of CA125 and CA125þHE4 in a study
with only 233 patients, one could expect that we should have been
able to show a significantly different result with our 389 patients,
which is the largest monocentre cohort study on HE4. In fact, if
one uses the AUCs of CA125 (0.836) and the combination of CA125
and HE4 (0.914) from the article of Moore et al, with an alpha level
of 0.05 and a beta level of 0.20, one can obtain a required minimum
sample size of 86 in each group. With a sample size of 389 patients,
we broadly exceeded the required number of samples.
The authors also suggest that there was a selection bias, with an
increased amount of cancers, postmenopausal patients, mucinous
tumours, borderline tumours and metastatic tumours of extra-
ovarian origin. Indeed, the bigger proportion of these specific
categories is a reflection of a patient population with adnexal
masses in a tertiary centre as ours. Recruitment was also largely
done in collaboration with our ultrasound department, which is an
expert centre in the diagnosis of pelvic masses (Timmerman et al,
2010). Hence, there was a relatively large proportion of stage I and
borderline tumours in our study, which are more difficult to
differentiate from their benign counterparts compared with stage
III or IV ovarian cancers. The fact that we were not able to show a
statistical difference between CA125 and ROMA illustrates that the
ROMA algorithm does not seem to be of any benefit in this
particular setting, which in our opinion is an important finding for
many centres. Moreover, in this setting, with more difficult
tumours to diagnose, the addition of a good diagnostic tumour
marker could have been of great importance, and yet, the addition
of HE4 to CA125 does not seem to fulfill these expectations.
Langma ´r et al also claim that the non-significant differences
between the AUCs of the different tests cannot exclude a gain in
diagnostic accuracy with statistical certainty. This strikes us as a
contradictio in terminis. As mentioned in the methods section, we
used the non-parametric method as described by DeLong et al
(1988) to calculate differences in AUCs. The method of DeLong
et al is the most widely used method to perform these
comparisons. We do not dispute the calculated differences in
AUCs and 95% confidence intervals by Langma ´r et al, but as the
P-level was 0.17 we were not able to reject the null hypothesis, and
thus in our setting this means that the results were not statistically
different. All comparisons and corresponding P-values are clearly
mentioned in our results section and are illustrated in the tables
and figures.
Finally, Langma ´r et al question our interpretation of the HE4
threshold. They state that the optimal threshold depends on the
characteristics of the population and the consequences of the true
and false test outcomes. Again, we fully agree with this last remark.
In the diagnosis of ovarian cancer one should try to detect as many
of the ovarian cancers as possible, and yet avoid unnecessary
surgeries for benign cysts. This implies that sensitivity is very
important; however, increasing morbidity, costs, pain and fear by
performing midline laparotomies for benign cysts are also
unacceptable. Therefore we have looked at the optimal cut-off
rather than a cut-off at a fixed sensitivity or specificity. As
mentioned in our article, the optimal cut-off corresponds to the
point on the ROC curve with the highest accuracy. As we did not
use healthy controls, we did not intend to find a cut-off for HE4
that could be used in screening. Moreover, we clearly stated that *Correspondence: Dr T Van Gorp; E-mail: toon.van.gorp@mumc.nl
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result in high specificity (96.5%), but in very low sensitivity
(50.3%). Therefore, a cut-off of 150 PM cannot be used in a
diagnostic situation in a population as ours. A cut-off of 70 PM is
more appropriate and very close to our calculated optimal cut-off
of 72.2 PM.
In conclusion, we understand that these negative results for this
promising HE4 marker and ROMA algorithm are disappointing.
We can only conclude that neither HE4 nor the combination of
HE4 and CA125 in the ROMA algorithm seems to be an
improvement in the diagnosis of ovarian cancer in patients with
an adnexal mass as referred to a tertiary centre as ours.
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